Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 2
1982 2
1983 2
1984 2
1985 3
1986 13
1987 10
1988 9
1989 12
1990 19
1991 13
1992 17
1993 20
1994 15
1995 15
1996 13
1997 15
1998 12
1999 12
2000 23
2001 19
2002 16
2003 12
2004 17
2005 26
2006 22
2007 24
2008 25
2009 24
2010 21
2011 30
2012 19
2013 25
2014 21
2015 26
2016 19
2017 13
2018 13
2019 24
2020 13
2021 14
2022 10
Text availability
Article attribute
Article type
Publication date

Search Results

625 results
Results by year
Filters applied: . Clear all
Page 1
CRRL269.
Chen Y, Harty GJ, Zheng Y, Iyer SR, Sugihara S, Sangaralingham SJ, Ichiki T, Grande JP, Lee HC, Wang X, Burnett JC Jr. Chen Y, et al. Among authors: burnett jc jr. Circ Res. 2019 May 10;124(10):1462-1472. doi: 10.1161/CIRCRESAHA.118.314164. Circ Res. 2019. PMID: 30929579 Free PMC article.
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Konstam MA, et al. Among authors: burnett jc jr. JAMA. 2007 Mar 28;297(12):1319-31. doi: 10.1001/jama.297.12.1319. Epub 2007 Mar 25. JAMA. 2007. PMID: 17384437 Clinical Trial.
Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial.
Ambrosy AP, Pang PS, Khan S, Konstam MA, Fonarow GC, Traver B, Maggioni AP, Cook T, Swedberg K, Burnett JC Jr, Grinfeld L, Udelson JE, Zannad F, Gheorghiade M; EVEREST Trial Investigators. Ambrosy AP, et al. Among authors: burnett jc jr. Eur Heart J. 2013 Mar;34(11):835-43. doi: 10.1093/eurheartj/ehs444. Epub 2013 Jan 4. Eur Heart J. 2013. PMID: 23293303
Designer natriuretic peptides.
Lee CY, Lieu H, Burnett JC Jr. Lee CY, et al. Among authors: burnett jc jr. J Investig Med. 2009 Jan;57(1):18-21. doi: 10.2310/JIM.0b013e3181946fb2. J Investig Med. 2009. PMID: 19158603 Free PMC article. Review.
Vasopeptidase inhibition.
Burnett JC. Burnett JC. Curr Opin Nephrol Hypertens. 2000 Sep;9(5):465-8. doi: 10.1097/00041552-200009000-00001. Curr Opin Nephrol Hypertens. 2000. PMID: 10990362 Review. No abstract available.
Natriuretic Peptides, Inflammation, and Sounding the Alarm.
Ramakrishnan V, Burnett JC Jr. Ramakrishnan V, et al. Among authors: burnett jc jr. Circ Heart Fail. 2020 Jul;13(7):e007208. doi: 10.1161/CIRCHEARTFAILURE.120.007208. Epub 2020 Jul 2. Circ Heart Fail. 2020. PMID: 32611204 Free PMC article. No abstract available.
Aptamer-siRNA chimeras for HIV.
Takahashi M, Burnett JC, Rossi JJ. Takahashi M, et al. Among authors: burnett jc. Adv Exp Med Biol. 2015;848:211-34. doi: 10.1007/978-1-4939-2432-5_11. Adv Exp Med Biol. 2015. PMID: 25757623 Review.
C-type natriuretic peptide: the heart's guardian angel.
Sangaralingham SJ, Chen Y, Burnett JC. Sangaralingham SJ, et al. Among authors: burnett jc. Eur Heart J. 2020 Mar 1;41(9):1021-1023. doi: 10.1093/eurheartj/ehz142. Eur Heart J. 2020. PMID: 30907411 Free PMC article. No abstract available.
Pharmacology of vasopressin antagonists.
Costello-Boerrigter LC, Boerrigter G, Burnett JC Jr. Costello-Boerrigter LC, et al. Among authors: burnett jc jr. Heart Fail Rev. 2009 Jun;14(2):75-82. doi: 10.1007/s10741-008-9108-8. Epub 2008 Sep 3. Heart Fail Rev. 2009. PMID: 18766438 Review.
625 results